GlassScriptPhysician profile
Laura D Ramirez
NPI 1225082894
$6,228.68
in general payments reported to CMS, 2019-2025
27 companies · $1,304 in 2025
The $1,304 reported for 2025 was more than what 85% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $564 · 2022: $1,508 · 2023: $1,522 · 2024: $1,332 · 2025: $1,304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,994 · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,993.65 |
| Education | $163.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,815.97 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $462.62 | 2021-2025 | |
| Lilly USA, LLC | $450.60 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $406.78 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $327.96 | 2021-2024 | Ilumya, Absorica Ld, Winlevi |
| Galderma Laboratories, L.P. | $312.14 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Amgen INC. | $300.82 | 2021-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $286.92 | 2021-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $276.16 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $228.05 | 2022-2024 | Tremfya |
| Dermavant Sciences, INC. | $214.63 | 2023-2024 | Vtama |
| Journey Medical Corporation | $209.62 | 2022-2024 | |
| Almirall LLC | $182.59 | 2022-2025 | Klisyri, Seysara |
| Incyte Corporation | $144.13 | 2023-2025 | Opzelura |
| Leo Pharma INC. | $143.49 | 2021-2025 | Adbry |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $82.82 | 2023-2025 | Cimzia, Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.99 | 2023-2025 | Spevigo, Cyltezo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $63.92 | 2021-2024 | Siliq, Duobrii, Targretin |
| Organon LLC | $57.78 | 2025 | Vtama |
| Pfizer INC. | $52.71 | 2022-2025 | |
| Vyne Pharmaceuticals INC. | $32.75 | 2021 | |
| Sumitomo Pharma America, INC. | $24.18 | 2024 | Gemtesa |
| Ani Pharmaceuticals, INC. | $20.75 | 2023 | Apexicon E |
| Mayne Pharma Commercial LLC | $17.96 | 2025 | |
| Medimetriks Pharmaceuticals, INC. | $16.07 | 2024 | Clindacin Etz |
| Paratek Pharmaceuticals, INC. | $14.90 | 2022 | |
| Avion Pharmaceuticals | $13.37 | 2024 | NP Thyroid 60 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.